the First Affiliated Hospital of Sun Yat-Sen University
🇨🇳China
Phase 2b Trial of Glecirasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer
A phase 2b trial investigates the efficacy of Glecirasib in treating KRAS G12C-mutated non-small-cell lung cancer, involving multiple institutions across China and the USA.
JMT103 Demonstrates Efficacy in Unresectable Giant Cell Tumor of Bone
• JMT103, a novel therapy, shows promising efficacy in treating unresectable or surgically-challenging giant cell tumor of bone (GCTB).
• The Phase Ib/II study demonstrated a notable objective tumor response rate (OTR) based on histopathological or radiological evaluation.
• Treatment with JMT103 led to clinically meaningful reductions in pain and improvements in daily functioning for GCTB patients.
• The safety profile of JMT103 was manageable, with adverse events consistent with the mechanism of action and manageable with supportive care.
© Copyright 2025. All Rights Reserved by MedPath